Bristol-Myers Squibb’s Immunoscience Products
Bristol-Myers Squibb’s (BMY) Immunoscience franchise includes Orencia, which is a fusion protein used for the treatment of rheumatoid arthritis and aligned problems.
Sep. 29 2017, Updated 9:11 a.m. ET
![uploads///Chart Orencia](https://media.marketrealist.com/brand-img/bImJnlTNQ/480x251/uploads/2017/09/Chart-07-Orencia-1.jpg 480w, https://media.marketrealist.com/brand-img/bImJnlTNQ/640x335/uploads/2017/09/Chart-07-Orencia-1.jpg 640w, https://media.marketrealist.com/brand-img/bImJnlTNQ/768x402/uploads/2017/09/Chart-07-Orencia-1.jpg 768w, https://media.marketrealist.com/brand-img/bImJnlTNQ/1024x536/uploads/2017/09/Chart-07-Orencia-1.jpg 1024w, https://media.marketrealist.com/brand-img/bImJnlTNQ/1280x670/uploads/2017/09/Chart-07-Orencia-1.jpg 1280w, https://media.marketrealist.com/brand-img/bImJnlTNQ/1440x753/uploads/2017/09/Chart-07-Orencia-1.jpg 1440w, https://media.marketrealist.com/brand-img/bImJnlTNQ/1600x837/uploads/2017/09/Chart-07-Orencia-1.jpg 1600w, https://media.marketrealist.com/brand-img/bImJnlTNQ/2160x1130/uploads/2017/09/Chart-07-Orencia-1.jpg 2160w)
Immunoscience products
Bristol-Myers Squibb’s (BMY) Immunoscience franchise includes Orencia, which is a fusion protein used for the treatment of rheumatoid arthritis and aligned problems.
The above chart shows revenues from Orencia over the last few quarters.
Orencia
Orencia is a drug that reduces the pain in moderate-to-severe rheumatoid arthritis and also helps to reduce further joint damage. Orencia reported 10% growth in revenues to $650 million in 2Q17, compared to revenues of $593 million in 2Q16. The growth in revenues was driven by an increase in sales in US as well as international markets.
Orencia reported 12% growth in US sales to $449 million in 2Q17, compared to revenues of $401 million in 2Q16.
Other brands from Bristol-Myers Squibb
The other brands from Bristol-Myers Squibb’s product portfolio include various products that have lost exclusivity in major markets, over-the-counter products, and royalty revenues. Overall, the revenues from other brands fell ~16% to $479 million in 2Q17, compared to $572 million for 2Q16.
Other brands reported a 5% fall in US sales to $92 million in 2Q17, compared to $97 million in 2Q16.
To divest company-specific risks, investors can consider ETFs like the First Trust NASDAQ Pharmaceuticals (FTXH), which invests 4.6% of its portfolio in Bristol-Myers Squibb (BMY). FTXH also invests 8.2% in Pfizer (PFE), 9.1% in Abbott Laboratories (ABT), and 4.1% in Eli Lilly and Co. (LLY).